Increasing evidence has shown the tumor-suppressive effect of PPAR agonists in several cancer, suggesting that the activation of PPARs could serve as a potential strategy for therapeutic treatment of, e.g., bladder cancer [83]. The gene discussed is PPARA; the disease is urinary bladder cancer.